1. Home
  2. RGLD vs EXAS Comparison

RGLD vs EXAS Comparison

Compare RGLD & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royal Gold Inc.

RGLD

Royal Gold Inc.

HOLD

Current Price

$277.55

Market Cap

20.6B

Sector

Industrials

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$102.13

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGLD
EXAS
Founded
1981
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.6B
19.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RGLD
EXAS
Price
$277.55
$102.13
Analyst Decision
Buy
Buy
Analyst Count
7
19
Target Price
$218.43
$81.27
AVG Volume (30 Days)
947.7K
2.3M
Earning Date
02-18-2026
02-18-2026
Dividend Yield
0.72%
N/A
EPS Growth
66.97
N/A
EPS
7.28
N/A
Revenue
$849,255,000.00
$3,082,033,000.00
Revenue This Year
$23.03
$19.40
Revenue Next Year
$71.74
$13.51
P/E Ratio
$36.42
N/A
Revenue Growth
28.17
14.47
52 Week Low
$135.68
$38.81
52 Week High
$265.48
$102.66

Technical Indicators

Market Signals
Indicator
RGLD
EXAS
Relative Strength Index (RSI) 84.79 79.87
Support Level $216.53 $101.51
Resistance Level $244.86 $102.56
Average True Range (ATR) 8.07 0.33
MACD 2.62 -0.62
Stochastic Oscillator 98.70 66.19

Price Performance

Historical Comparison
RGLD
EXAS

About RGLD Royal Gold Inc.

Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: